Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05487170 · ClinicalTrials.gov registry record · Phase 1

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

A Phase 1 study of Advanced Solid Tumor and DLBCL, sponsored by Ranok Therapeutics (Hangzhou) Co..

Recruiting
Registry status
Phase 1
Development phase
32
Enrollment target
5
Study locations

NCT05487170: Recruiting Phase 1 study of Advanced Solid Tumor and DLBCL, sponsored by Ranok Therapeutics (Hangzhou) Co..

NCT05487170 is a Phase 1 study of Advanced Solid Tumor and DLBCL that is actively recruiting participants, run by Ranok Therapeutics (Hangzhou) Co.. The registered enrollment target is 32 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05487170, a Phase 1 study of Advanced Solid Tumor and DLBCL, is actively recruiting participants, sponsored by Ranok Therapeutics (Hangzhou) Co..

RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
5
Study locations

Study Summary

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.

Conditions Studied

Advanced Solid Tumor DLBCL

Interventions

  • DRUG RNK05047

Study Locations (5)

Beijing Municipality

  • Cancer Hospital, Chinese Academy of Medical Sciences - Beijing
  • Beijing Cancer Hospital - Beijing

Georgia

  • Emory University Winship Cancer Institute - Atlanta

Kentucky

  • Norton Cancer Institute - Louisville

New York

  • Weill Cornell - NY Presbyterian Hospital - New York

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2022-07-12
Est. Completion 2025-09-01
Phase Phase 1
Ranok Therapeutics (Hangzhou) Co.

1 total trials

What NCT05487170 shows while recruiting

NCT05487170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which RNK05047 is the first listed.

NCT05487170 lists 5 locations in 4 states (Beijing Municipality, Georgia, Kentucky).

Frequently Asked Questions

What is clinical trial NCT05487170 about?

NCT05487170 is a clinical study titled "A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)". This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL...

What is the current status of trial NCT05487170?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-07-12. Estimated completion is 2025-09-01.

What conditions does trial NCT05487170 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, DLBCL.

What interventions are being tested in trial NCT05487170?

The interventions under investigation include: RNK05047 (DRUG).

Who is sponsoring clinical trial NCT05487170?

This trial is sponsored by Ranok Therapeutics (Hangzhou) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05487170 being conducted?

This trial has 5 study locations across Georgia, Kentucky, New York, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05487170's enrollment target sits among peer trials

32 174th of 189 higher than 16 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05487170

Source: ClinicalTrials.gov NCT05487170, the US trial registry maintained by the National Library of Medicine. NCT05487170 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.